Ways2Capital Reviews : Sun Pharma Stock Soars 7% After Announcing Q4 Numbers

Sun Pharmaceuticals Industries Ltd is currently trading at Rs500.10 up by Rs33.55 or 7.19% from its previous closing of Rs466.55 on the BSE.

The company’s PAT grew by 15.5% yoy to Rs1,552.3cr in Q4FY18. EBITDA grew by 8.8% yoy to Rs1,683.5cr in Q4FY18. EBITDA margins were at 24.1% in Q4FY18 vs. 21.8% in Q3FY18 and 21.7% in Q4FY17.

The quarter includes one-off, exceptional items, tax write-back of Rs258.6cr on account of difference on tax and book value on the intra-group transfer of certain intangibles. Adjusted for this one-off item, PAT would have been at Rs1,294cr, still ahead of the street estimate of Rs854cr for Q4FY18.

The scrip opened at Rs487.70 and has touched a high and low of Rs504.70 and Rs481.70 respectively.

Sun Pharma is the largest Indian pharma company by revenue and market cap. It is one of the strongest brand franchises in domestic pharma market. Its US business has been mostly built inorganically by acquiring Taro, Caraco, Dusa, etc.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai